Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02654119

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Stage IIB Breast Cancer AJCC v6 and v7 Clinical Trial

Official title:
A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer Patients

Clinical Trial Summary

This phase II trial studies the side effects and how well cyclophosphamide, paclitaxel, and trastuzumab work when given after surgery in treating patients with stage I-II human epidermal growth factor receptor (HER2/neu) positive breast cancer (confined to the breast or the breast and lymph nodes under the arm). Drugs used in chemotherapy, such as cyclophosphamide and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, may interfere with the ability of tumor cells to grow and spread. Giving cyclophosphamide, paclitaxel, and trastuzumab after surgery may help prevent the cancer from coming back.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the toxicities and ability to complete the planned treatment of a dose-dense regimen of cyclophosphamide and paclitaxel with trastuzumab in subjects with newly diagnosed stage I-II HER2/neu positive breast cancer. II. To estimate recurrence free survival of a dose-dense regimen of cyclophosphamide and paclitaxel with trastuzumab in subjects with newly diagnosed stage I-II HER2/neu positive breast cancer. OUTLINE: SYSTEMIC THERAPY: Patients receive cyclophosphamide intravenously (IV) over 1 hour, paclitaxel IV over 3 hours, and trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE TRASTUZUMAB THERAPY: Beginning in course 6, patients receive trastuzumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may undergo radiation therapy at the discretion of the radiation oncologist and medical oncologist and patients with estrogen/progesterone receptor positive tumors receive hormonal therapy as determined by the medical oncologist per standard National Comprehensive Care Network (NCCN) guidelines. After completion of study treatment, patients are followed up every 3 months for 2 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02654119
Study type Interventional
Source University of Nebraska
Contact
Status Active, not recruiting
Phase Phase 2
Start date December 11, 2015
Completion date November 20, 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT02689427 - Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer Phase 2
Active, not recruiting NCT02754752 - Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment Phase 2
Completed NCT03094052 - Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib Phase 2
Active, not recruiting NCT03317405 - Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery Phase 1
Recruiting NCT02276443 - Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative N/A
Active, not recruiting NCT01245712 - Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer Phase 2
Completed NCT00005970 - Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer Phase 3
Active, not recruiting NCT00861705 - Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Phase 2
Recruiting NCT03391453 - Proton Beam Radiation Therapy in Treating Patients With Breast Cancer After Surgery Phase 2
Completed NCT03454529 - The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer Phase 2
Active, not recruiting NCT03077841 - Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer Phase 2/Phase 3
Active, not recruiting NCT03012100 - Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Phase 2
Completed NCT03407716 - Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors Early Phase 1
Active, not recruiting NCT02079662 - The Role of Lifestyle Factors in Breast Cancer-Related Outcomes N/A
Active, not recruiting NCT04054557 - Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence N/A
Completed NCT03568526 - Sensorimotor Rehabilitation Program in Improving Quality of Life in Patients With Early Stage Breast Cancer N/A
Completed NCT03319342 - Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors N/A
Active, not recruiting NCT01275677 - Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Phase 3
Recruiting NCT02945579 - Eliminating Surgery or Radiotherapy After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer N/A
Active, not recruiting NCT02003209 - Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Phase 3